stoxline Quote Chart Rank Option Currency Glossary
  
Mereo BioPharma Group plc (MREO)
2.9  0 (0%)    02-12 16:00
Open: 2.9
High: 2.94
Volume: 788,001
  
Pre. Close: 2.9
Low: 2.8
Market Cap: 449(M)
Technical analysis
2025-02-12 4:46:33 PM
Short term     
Mid term     
Targets 6-month :  4.02 1-year :  4.48
Resists First :  3.44 Second :  3.83
Pivot price 3
Supports First :  2.79 Second :  2.32
MAs MA(5) :  3 MA(20) :  2.99
MA(100) :  3.71 MA(250) :  3.65
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  30 D(3) :  45.4
RSI RSI(14): 38.9
52-week High :  5.01 Low :  2.52
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MREO ] has closed above bottom band by 25.0%. Bollinger Bands are 44.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.94 - 2.96 2.96 - 2.98
Low: 2.76 - 2.78 2.78 - 2.8
Close: 2.87 - 2.9 2.9 - 2.93
Company Description

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Headline News

Tue, 11 Feb 2025
Mereo BioPharma: Good Science, Fairly Valued (NASDAQ:MREO) - Seeking Alpha

Sat, 25 Jan 2025
Brokerages Set Mereo BioPharma Group plc (NASDAQ:MREO) Target Price at $7.83 - MarketBeat

Mon, 13 Jan 2025
Mereo Biopharma Advances with Key Clinical Updates - TipRanks

Sun, 12 Jan 2025
Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewswire

Tue, 07 Jan 2025
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Mon, 30 Dec 2024
Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 155 (M)
Held by Insiders 4.8993e+008 (%)
Held by Institutions 1 (%)
Shares Short 7,050 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.748e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 806.5 %
Return on Equity (ttm) -30.7 %
Qtrly Rev. Growth 1e+006 %
Gross Profit (p.s.) 0
Sales Per Share -49.97
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 7.2e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android